Canada Pension Plan Investment Board Bluebird Bio, Inc. Transaction History

Canada Pension Plan Investment Board

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$4.07 - $10.6 $11,245 - $29,287	-2,763 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.96 - $16.31 $2,956 - $5,382	330 Added 13.56%	2,763 $28,000
Q3 2021 Nov 15, 2021	SELL	$11.24 - $21.0 $3.6 Million - $6.73 Million	-320,252 Reduced 99.25%	2,433 $46,000
Q2 2021 Aug 16, 2021	BUY	$18.04 - $22.09 $4.7 Million - $5.75 Million	260,373 Added 417.85%	322,685 $10.3 Million
Q1 2021 May 17, 2021	BUY	$16.59 - $33.89 $30,326 - $61,950	1,828 Added 3.02%	62,312 $1.88 Million
Q4 2020 Feb 17, 2021	BUY	$27.5 - $37.92 $1.33 Million - $1.83 Million	48,286 Added 395.85%	60,484 $2.62 Million
Q3 2020 Nov 12, 2020	SELL	$34.44 - $43.75 $151,260 - $192,150	-4,392 Reduced 26.47%	12,198 $658,000
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $75,013 - $127,153	2,766 Added 20.01%	16,590 $1.01 Million
Q1 2020 May 13, 2020	BUY	$26.16 - $63.5 $218,069 - $529,336	8,336 Added 151.9%	13,824 $636,000
Q4 2019 Feb 14, 2020	BUY	$46.96 - $61.67 $257,716 - $338,444	5,488 New	5,488 $482,000

27M

191K

299K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $561M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Canada Pension Plan Investment Board, based on Form 13F filings with the SEC.

Stay updated on Canada Pension Plan Investment Board with notifications on news.